skip to Main Content

AntiCancer’s Oral Drug Overcomes Gemcitabine Resistance in Mouse Models of Human Pancreatic Cancer

AntiCancer’s Oral Drug Overcomes Gemcitabine Resistance in Mouse Models of Human Pancreatic Cancer
Pancreatic cancer is lethal in about 95% of cases mostly due to failure of first-line therapy gemcitabine.

AntiCancer Inc.’s oral methioninase (AC 00619), which is in late pre-clinical development as an anti-cancer as well as an anti-aging drug, has now been shown to overcome gemcitabine resistance in mouse models of human pancreatic cancer, including AntiCancer’s patient-derived orthotopic xenograft (PDOX®) mouse models. The new results are to be published in the upcoming issue of Cancer Letters. Read more . . . 


Back To Top